NASDAQ:SCNI
Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. reported net income of −$5.8M in fiscal 2022. Free cash flow was −$8.1M, and the diluted share count rose 33.6%.Summary generated from Scinai Immunotherapeutics Ltd.'s SEC filings. Latest annual report filed Apr 17, 2023.
Key statistics
Fiscal 2022 from SEC filings. MethodologyRevenue (FY22)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$8.1M
FCF marginn/a
Share count change+33.6%
Financials
| Item | 2021 | 2022 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | −11 | −11 |
| Net income | −8 | −6 |
| Free cash flow | −8 | −8 |
Recent filings
- 4Insider transaction report
Jun 18, 2026 - 4Insider transaction report
Jun 18, 2026 - 8-KEntry into a material agreement
Jun 8, 2023 - 10-QQuarterly report for the period ended Mar 31, 2023
May 15, 2023 - 8-KDirector or officer change
May 11, 2023 - 8-KNotice of delisting or listing-rule failure
May 4, 2023 - 8-KRegulation FD disclosure
May 4, 2023 - 10-KAnnual report for the fiscal year ended Dec 31, 2022
Apr 17, 2023